Terms: = Leukemia AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M
854 results:
1. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract] [Full Text] [Related]
2. [Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid leukemia --Review].
Ye F; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):630-633. PubMed ID: 38660877
[TBL] [Abstract] [Full Text] [Related]
3. RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in idh-mutated AML cells.
Zhu S; Luo Y; Li K; Mei C; Wang Y; Jiang L; Wang W; Zhang Q; Yang W; Lang W; Zhou X; Wang L; Ren Y; Ma L; Ye L; Huang X; Chen J; Sun J; Tong H
Sci Adv; 2024 Apr; 10(16):eadi1782. PubMed ID: 38630819
[TBL] [Abstract] [Full Text] [Related]
4. A Case of Chronic Eosinophilic leukemia with CSF3R-Mutant Clone and Transformed to Secondary Acute Myeloid leukemia.
Wu Y; Yang X
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623671
[TBL] [Abstract] [Full Text] [Related]
5. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Fruchtman H; Avigan ZM; Waksal JA; Brennan N; Mascarenhas JO
Leukemia; 2024 May; 38(5):927-935. PubMed ID: 38600315
[TBL] [Abstract] [Full Text] [Related]
6. Data-driven modeling of core gene regulatory network underlying leukemogenesis in idh mutant AML.
Katebi A; Chen X; Ramirez D; Li S; Lu M
NPJ Syst Biol Appl; 2024 Apr; 10(1):38. PubMed ID: 38594351
[TBL] [Abstract] [Full Text] [Related]
7. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory idh2-mutated AML.
Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
[TBL] [Abstract] [Full Text] [Related]
8. Clinical features and management of germline CEBPA-mutated carriers.
Pan L; Li Y; Gao H; Lai X; Cai Y; Chen Z; Li X; Wang SY
Leuk Res; 2024 Mar; 138():107453. PubMed ID: 38442594
[TBL] [Abstract] [Full Text] [Related]
9. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
10. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
Bouligny IM; Murray G; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Ho T; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Med Oncol; 2024 Feb; 41(3):80. PubMed ID: 38396145
[TBL] [Abstract] [Full Text] [Related]
11. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
[TBL] [Abstract] [Full Text] [Related]
12. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
13. idh2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
[TBL] [Abstract] [Full Text] [Related]
14. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract] [Full Text] [Related]
15. Altered Oxidative Phosphorylation Confers Vulnerability on idh1-Mutant leukemia Cells: Is This Therapeutically Tractable?
Steensma DP
Blood Cancer Discov; 2024 Mar; 5(2):83-85. PubMed ID: 38331418
[TBL] [Abstract] [Full Text] [Related]
16. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
Gunn K; Losman JA
Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
[TBL] [Abstract] [Full Text] [Related]
17. Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India.
Singh N; Gupta A; Kumar S; Mawalankar G; Gupta B; Dhole N; Kori R; Singh A
J Hematop; 2023 Mar; 16(1):17-25. PubMed ID: 38175369
[TBL] [Abstract] [Full Text] [Related]
18. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Le Rhun E; Gorlia T; Felsberg J; Jongen J; Maurage CA; Ducray F; Gramatzki D; Hau P; Chinot OL; Preusser M; Cartalat S; Roth P; van den Bent M; Furtner J; Collienne M; Reifenberger G; Weller M
Eur J Cancer; 2024 Feb; 198():113475. PubMed ID: 38159337
[TBL] [Abstract] [Full Text] [Related]
19. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
20. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
[Next]
